Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies.
about
Glucagon orchestrates stress-induced hyperglycaemiaPancreatic α-cell hyperplasia and hyperglucagonemia due to a glucagon receptor splice mutationPharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD-6972 in healthy subjects and subjects with type 2 diabetes mellitus.Glucagon: acute actions on hepatic metabolism.The New Biology and Pharmacology of Glucagon.Angptl4 does not control hyperglucagonemia or α-cell hyperplasia following glucagon receptor inhibition.Pas de Deux: Glucagon and Thyroid Hormone Moving in Perfect Synchrony.Regulation of hepatic glucose metabolism in health and disease.GLP-1/glucagon receptor co-agonism for treatment of obesity.Treatment with the glucagon receptor antagonist LY2409021 increases ambulatory blood pressure in patients with type 2 diabetes.Impaired Insulin Action Is Associated With Increased Glucagon Concentrations in Nondiabetic Humans.Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes.Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes.Current Therapies That Modify Glucagon Secretion: What Is the Therapeutic Effect of Such Modifications?Glucagon receptor as a drug target: A witches' brew of eye of newt (peptides) and toe of frog (receptors).A first-in-human pharmacodynamic and pharmacokinetic study of a fully human anti-glucagon receptor monoclonal antibody in normal healthy volunteers.Insulin deficiency with and without glucagon: A comparative study between total pancreatectomy and type 1 diabetes.Glucagon Receptor Antagonism Improves Glucose Metabolism and Cardiac Function by Promoting AMP-Mediated Protein Kinase in Diabetic Mice.Problem or solution: The strange story of glucagon.Effects of multiple ascending doses of the glucagon receptor antagonist PF-06291874 in patients with type 2 diabetes mellitus.Synthesis of C-14 radiolabeled glucagon receptor antagonist and its use in a human mass balance study.Clinical Trials, Triumphs, and Tribulations of Glucagon Receptor Antagonists.Chronic fractalkine administration improves glucose tolerance and pancreatic endocrine function.Coding variants in PNPLA3 and TM6SF2 are risk factors for hepatic steatosis and elevated serum alanine aminotransferases caused by a glucagon receptor antagonist.Deletion of the glucagon receptor gene before and after experimental diabetes reveals differential protection from hyperglycemia
P2860
Q28068879-4D44E924-7B09-4708-B17D-ACB2751E3EF2Q37428588-E8FCDD3A-708A-486C-BCC0-06F05BC7F571Q37561118-1FCB01A2-0FC3-4A5B-AF73-0E07309E5796Q38817842-4F437356-17C3-4630-901A-71283BABC9BEQ38919742-60C295E0-BFBA-4A83-9D11-995CA94EAB45Q38988157-75112E83-377A-461E-AC72-EF92D3D29A34Q39158809-A2D86B79-0295-4CCE-A029-29E8321F18C3Q39450184-99D87AE3-5121-463D-A9FE-71E6D7DB2628Q39451553-CF003F09-9EFF-4B53-8732-D094AE2A86B3Q46378864-9CB7FCB1-2E22-48F5-95CF-963432864AA9Q47360675-25A759CD-69DA-4041-B1E9-B537C369371CQ47566343-EAE7BFED-97E8-41A9-8FBB-D117BA37256BQ47625288-4791AA28-7FBE-48DB-B757-05BC357A5675Q47871565-60255B1F-677A-4749-9BBA-EECFF46C5398Q48171528-4ADEC8E4-50C4-40FB-A9C8-318AD39323E7Q48326278-6364F105-20FA-4C83-8790-78AA7E55C30DQ48329250-5641CC58-F939-4093-B7A9-34B95F4AD2AAQ49997196-DF849C37-C4F7-430F-90BC-02A7AFE5DFF8Q50140641-B501E9EF-932D-4A79-B230-E7B6E33859F7Q51286181-74A13BEB-0D75-4233-B11E-B8B38C5519B3Q51290600-7FB9329F-2252-45B1-9394-3C98D966EBA5Q51689139-38C49A11-F2B6-48A9-970A-FA3B66CF4D78Q52674221-10F73F55-465E-4FEE-94CC-1A28FE420495Q55032630-672C9158-816C-4441-BC9F-AF6F68253DD6Q58732217-4C6B3BA7-FE04-4CF1-A665-E8540F6F1AF3
P2860
Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Evaluation of Efficacy and Saf ...... - and 24-Week Phase 2 Studies.
@en
Evaluation of Efficacy and Saf ...... - and 24-Week Phase 2 Studies.
@nl
type
label
Evaluation of Efficacy and Saf ...... - and 24-Week Phase 2 Studies.
@en
Evaluation of Efficacy and Saf ...... - and 24-Week Phase 2 Studies.
@nl
prefLabel
Evaluation of Efficacy and Saf ...... - and 24-Week Phase 2 Studies.
@en
Evaluation of Efficacy and Saf ...... - and 24-Week Phase 2 Studies.
@nl
P2093
P356
P1433
P1476
Evaluation of Efficacy and Saf ...... - and 24-Week Phase 2 Studies.
@en
P2093
Andrew J Lewin
Chay Ngee Lim
Christof M Kazda
Chunxue Shi
David E Moller
David E Watson
Mark A Deeg
Parag Garhyan
Ronan P Kelly
P304
P356
10.2337/DC15-1643
P407
P577
2015-12-17T00:00:00Z